APA (7th ed.) Citation

Banz, K., Bischoff, H., Brunner, M., Chouaid, C., Castro Carpeño, J. d., Marinis, F. d., . . . Walzer, S. (2011). Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung cancer, 74(3), . https://doi.org/10.1016/j.lungcan.2011.04.010

Chicago Style (17th ed.) Citation

Banz, Kurt, Helge Bischoff, Matthias Brunner, Christos Chouaid, Javier de Castro Carpeño, Filippo de Marinis, Francesco Grossi, Alain Vergnenègre, and Stefan Walzer. "Comparison of Treatment Costs of Grade 3/4 Adverse Events Associated with Erlotinib or Pemetrexed Maintenance Therapy for Patients with Advanced Non-small-cell Lung Cancer (NSCLC) in Germany, France, Italy, and Spain." Lung Cancer 74, no. 3 (2011). https://doi.org/10.1016/j.lungcan.2011.04.010.

MLA (9th ed.) Citation

Banz, Kurt, et al. "Comparison of Treatment Costs of Grade 3/4 Adverse Events Associated with Erlotinib or Pemetrexed Maintenance Therapy for Patients with Advanced Non-small-cell Lung Cancer (NSCLC) in Germany, France, Italy, and Spain." Lung Cancer, vol. 74, no. 3, 2011, https://doi.org/10.1016/j.lungcan.2011.04.010.